Posts by camerontucker
From Sample to Signal: How Biospecimen Quality Impacts Multiomic Assay Development
From Sample to Signal: How Biospecimen Quality Impacts Multiomic Assay Development Multiomic research allows scientists to examine biology across multiple layers, combining information from genomics, transcriptomics, epigenetics, proteomics, and other molecular measurements. By integrating these different data types, researchers can develop a more complete picture of cellular function, disease progression, treatment response, and biological variation.…
For More InformationThe Infrastructure Behind Allogeneic Cell Therapy: Why Donor Programs Matter More Than Ever
The Infrastructure Behind Allogeneic Cell Therapy: Why Donor Programs Matter More Than Ever Cell and gene therapy has entered a new phase. For years, the industry’s primary goal was proving these therapies could work. Today, many of those questions have been answered. CAR T therapies have demonstrated remarkable outcomes in certain blood cancers, and hundreds…
For More InformationCGT Global Appoints Charlotte Ivancic to Board of Advisors, Strengthening Strategic Leadership in Cell and Gene Therapy Policy and Market Access
Charlotte Ivancic brings more than 18 years of experience on Capitol Hill, where she played a key role in shaping healthcare legislation and advising senior leadership in both the U.S. Senate and House of Representatives. Her deep expertise in healthcare policy, reimbursement, and patient access will be instrumental as CGT Global advances the field of…
For More InformationLeukopak vs PBMC vs Whole Blood: What’s the Difference and Which One Do You Need?
Leukopak vs PBMC vs Whole Blood: What’s the Difference and Which One Do You Need? Cell therapy, immunology, and translational research programs all rely on high quality human blood derived materials. But one of the most common sourcing questions researchers face is: Should I use whole blood, PBMCs, or a leukopak? The answer depends on…
For More InformationT Cell Activation in Cell Therapy: Why T Cell Activation Fails Without the Right Starting Material
Introduction T cell activation is a foundational step in cell and gene therapy workflows, particularly in CAR T and other adoptive cell therapies. While much attention is placed on genetic engineering and manufacturing scale, activation is where functional outcomes begin to take shape. When done correctly, it enables strong expansion, optimal phenotypes, and durable responses.…
For More InformationWhy CGT Global Is Positioned to Support the Next Wave of Cell and Gene Therapies
Cell and gene therapy companies rely on several critical pieces of infrastructure to move therapies from development to clinical trials and ultimately to patient treatment. These include reliable sources of GMP compatible starting material, clinical trial support for complex cell therapy workflows, and hospitals capable of administering advanced therapies. Without these components in place, even…
For More InformationBulk CD34+ Isolation from Mobilized Leukopaks: GCSF vs GCSF + PLX vs PLX
Bulk CD34+ isolation is critical for stem cell therapy development, gene editing workflows, and advanced cell therapy research. When programs require large scale CD34+ recovery, the mobilization strategy used prior to leukapheresis directly impacts yield potential, scheduling timelines, and operational efficiency. Understanding the differences between GCSF mobilization, GCSF + PLX mobilization, and PLX only mobilization…
For More InformationB Cell CAR T in Autoimmune Disease Breaks for Predictable Operational Reasons
B Cell CAR T in Autoimmune Disease Breaks for Predictable Operational Reasons B cell directed CAR T programs in autoimmune disease rarely fail because of the cell. They stall because operational assumptions borrowed from oncology do not hold once real patients and real timelines enter the picture. Teams often discover this late, usually after their…
For More InformationBlood Types Explained
What your blood type means and why it matters for donation and research Learn how ABO and Rh blood types work, how common each type is, and why donors are essential for lifesaving care and medical research. CGT Global donors are compensated from $25 and up to $1,000 for your time and effort depending on…
For More InformationFrom Donor Recall to Data Integrity: The Operational Backbone of Ex Vivo Cell Therapy
By Eliona Kola, Process Development Scientist “Hey Sophie, will the lab receive the leukopak from the recall donor tomorrow for the CD3⁺ isolations?” That’s a question we ask our Director of Logistics Operations who also leads our Donor Scheduling Department more often than not. Coordinating around a donor’s availability can be challenging for any team,…
For More Information